thelancet.com
Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlle...
In young people with recent-onset, clinical type 1 diabetes, 2·5 mg/kg and 0·5 mg/kg
ATG reduced loss of β-cell function, showing the potential of an affordable, repurposed
agent, ATG, in a low and sa...